Strathspey Crown

Strathspey Crown acquires Evolus

Friday, October 4, 2013

Strathspey Crown, a growth equity firm specializing in lifestyle healthcare, has acquired Evolus of Santa Barbara, Calif., for an undisclosed amount. Strathspey Crown’s wholly-owned subsidiary Alphaeon, a lifestyle healthcare company, has received the exclusive license to market, in both the U.S. and several international markets, an advanced Botulinum toxin Type A neurotoxin developed by Daewoong Pharmaceutical, based in Seoul, South Korea. The Botulinum toxin Type A product will be marketed by Alphaeon under the brand name Evosyal. The exclusive license also includes certain rights associated with future neurotoxin developments by Daewoong Pharmaceutical.

[Read More]